The technical system that completely controls the distribution of pharmaceuticals throughout the body in terms of space, time, and dose is referred to as drug delivery technology. Drug delivery should solve the controlled release and targeted delivery problems for pharmaceuticals in the delivery category as well as the water solubility and stability problems for drugs in the preparation category.Drug delivery and release positions can be controlled, drug metabolism in vivo can be altered, physiological barriers can be crossed to boost drug absorption, drug bioavailability can be increased, therapeutic efficacy can be improved, and harmful side effects can be simultaneously reduced. Although viral vectors are effective at delivering nucleic acids and have some targeting capabilities, it is important to take into account the challenges of recurrent drug delivery and significant immunogenicity.RNA vaccines and therapies have been effectively delivered using the LNP delivery method, however due to its lack of targeting and inability to cross the blood-brain barrier, it is difficult to play a role in several therapeutic fields.
The Drug Delivery Vehicle Therapeutic Platform (ANEXT Super Delivery®) uses a variety of bioengineering techniques to address the exosomes' low loading efficiency, impurities, and targeting issues while designing advantageous targeting components and creating efficient exosome loading strategies for the best possible innovative drug discovery.
• Exosomes - a natural and efficient "logistics system" for drug delivery.
• Highly biocompatible, no antigen-antibody reaction, easy to cross cell, tissue and organ barriers (blood-brain barrier, blood-fetal barrier, etc.).
• It shines in the areas of disease diagnosis, oncology treatment, treatment of chronic diseases and treatment of inflammatory injuries.
• Multiple forms of treatment can be combined, promising to overcome clinical pain points.
The features of exosomes, such as endogenous origin, tiny particle size (30nm-150nm), and the capacity to pass the blood-brain barrier, make them good candidates for drug carriers. The therapeutic use of exosomes has been constrained, nonetheless, by issues with exosome extraction, characterisation, and quality control, rapid bodily circulation clearance, inadequate targeting capability, and ambiguous loading effectiveness. Therefore, the ANEXT Super Delivery® platform is a useful technique to get over current constraints and investigate its necessary therapeutic agent loading capabilities.
Address: No. 1788, West Huifeng Road, Fengxian District, Shanghai, China
phone: 02160133720
